Novo Nordisk has reported the second phase 3 trial of its new obesity hopeful CagriSema but, as with the first, the topline ...

Investing.com -- Novo Nordisk’s stock has dropped around 6.6% in premarket trading Monday following the release of its latest ...

U.S. stock futures point lower after a volatile week of trading and President Donald Trump's comments from a weekend ...

Novo Nordisk shares declined on Monday after the company reported that its next-generation weight-loss drug, CagriSema, ...

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Here are the most important news items that investors need to start their trading day: ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...